A European investor required due diligence on a lead preclinical candidate being developed by a biotech company for the treatment and prevention of aortic valve stenosis (AVS). Alacrita was commissioned to validate the company’s clinical strategy and to gain an understanding of probable uptake and pricing in both Europe and the US.
Alacrita conducted primary research with experienced payers and clinical cardiologists in Europe and the US. The former allowed us to gain insights into HTA assessment and reimbursement expectations, evaluate pricing assumptions and to generate new pricing models in both markets. Discussions with clinicians afforded expert opinion on the target company's clinical trial strategy and expected positioning in the treatment landscape. Our research and conclusions were condensed into a full analysis report and delivered to the client.
As the demands of the pharmaceutical market rise, and new products challenge established principles, it is more important than ever that product strategies meet the needs of providers, payers and patients. We can help.